GenMark Diagnostics (GNMK) Set to Announce Earnings on Tuesday
GenMark Diagnostics (NASDAQ:GNMK) will be posting its quarterly earnings results after the market closes on Tuesday, April 30th. Analysts expect GenMark Diagnostics to post earnings of ($0.19) per share for the quarter. GenMark Diagnostics has set its FY 2019 guidance at EPS.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Thursday, February 21st. The medical equipment provider reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.05). The company had revenue of $19.38 million during the quarter, compared to analyst estimates of $19.22 million. GenMark Diagnostics had a negative net margin of 71.37% and a negative return on equity of 107.77%. On average, analysts expect GenMark Diagnostics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ:GNMK opened at $7.00 on Tuesday. GenMark Diagnostics has a one year low of $3.58 and a one year high of $8.81. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 1.07. The company has a market cap of $395.30 million, a PE ratio of -7.69 and a beta of 1.57.
An institutional investor recently raised its position in GenMark Diagnostics stock. Geode Capital Management LLC increased its position in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 594,807 shares of the medical equipment provider’s stock after acquiring an additional 29,902 shares during the quarter. Geode Capital Management LLC owned about 1.06% of GenMark Diagnostics worth $2,890,000 as of its most recent SEC filing. 94.21% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Saturday, February 23rd. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of GenMark Diagnostics in a research report on Friday, February 22nd. Finally, Zacks Investment Research upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $9.75.
TRADEMARK VIOLATION NOTICE: “GenMark Diagnostics (GNMK) Set to Announce Earnings on Tuesday” was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/genmark-diagnostics-gnmk-set-to-announce-earnings-on-tuesday/2982130.html.
GenMark Diagnostics Company Profile
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Recommended Story: Do stock splits help investors?
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.